

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-68)

IXOBEROGENE SOROPARVOVEC

PRONUNCIATION

ix" oh ber' oh jeen sor" oh par' voe vec

THERAPEUTIC USE

Treatment of age-related neovascular (wet) macular degeneration (nAMD)

DESCRIPTION


DNA (recombinant adeno-associated virus vector ADVM-022 human cytomegalovirus promoter plus (1-26)-(129-232)-human vascular endothelial growth factor receptor 1 fusion protein with 227-327-human vascular endothelial growth factor receptor 2 fusion protein with human immunoglobulin G1 γ 1-chain C-terminal fragment transgene plus human growth hormone polyadenylation signal plus adeno-associated virus 2 inverted terminal repeat flanks-specifying) (CA INDEX NAME)

SEQUENCE

```
1   atgggtgcat actgggatac tggagtcttg ctttgtgccc tgctgtcctg
51  cctcctcctg actggctcca gctcgggctc agataccggg cggcccttcg
101 tggagatgta ctccgagatc ccggaata tccacatgac tgaggggcg
151 gaacttgtga tcccctgccg ggtcaccagc ccgaacatta ctgtgacttt
201 gaagaagttc cccctggaca ccctgattcc ggatgggaag agaattatct
251 gggattcacg gaagggattc atcatcagca acgcgacctc caaggaaatt
301 ggcctcctca cttgcgaagc cactgtgaac ggacacttgt acaagaccaa
351 ctacctgacc caccgccaga ccaacacatc catcgacgtc gtctgttccc
401 cttcgcacgg gatcgagctc tcgggtgggag agaagttggg gcttaactgc
451 accgcccgga cggaactgaa tgtgggaatc gacttcaact ggggaataccc
501 gtccagcaag catcagcata agaagctggg gaaccgggac ctcaagactc
551 agtccggcag cgaaatgaag aagttcctgt cgaccctcac tattgacgga
601 gtgaccagat ccgaccaggg cctctacact tgcgccgctt ccagcggact
651 catgaccaag aagaacagca ctttcgtgag ggtgcatgag aaggacaaga
701 cccacacgtg tccgccgtgc ccagccccag agctgctggg aggcccttcc
751 gtgttctctg ttccgcccga gccaaaggat accctgatga tctcaaggac
801 ccctgaggtc acatgcgtcg tgggtgatgt gtcgcacgag gaccctgaag
851 tcaaattcaa ttggtatgtg gacggagtgg aagtcacaa cgcgaaaacc
901 aagccgagag aagaacagta caattccacc taccgggtgg tgtcgggtgt
951 gactgtgctg caccaggact ggctcaacgg aaaggagtac aagtgcgaag
1001 tgtccaacaa ggctctgccc gcacctattg aaaagacatc ctccaaggcc
1051 aagggctaac ctcgcgagcc tcaggtgtac actctgcctc caagccggga
1101 cgaactgact aagaaccaag tctctctgac ctgtttgggt aagggcttct
1151 acccgtcaga catcgcagtg gagtgggagt caaacgggtc gccggagaac
1201 aactacaaa caaccccccc cgtgctggac tccgacggct ctttcttctt
1251 gtactccaag cttaccgtgg ataagagccg ctggcaacag ggcaacgtgt
1301 tttctgtctc cgtcatgcac gaagccctgc acaaccatta taccagaag
1351 tccctgtcgc tgtcccccg gaaatag
```

SCHEMATIC MAP

Structure of the ADVM-022 Genome Vector



Legend:

ITR = AAV2 Inverted Terminal Repeat Sequence; C11 = Cassette

TRADEMARK	None yet
SPONSOR	Adverum Biotechnologies
CODE DESIGNATION	ADVM-022
<u>CAS</u> REGISTRY NUMBER	2538429-16-0
UNII	MFB3FSW75U
WHO NUMBER	12109

SCS